SCHEMBL131050

SCHEMBL131050

COC(=O)CC[C@H](N)C(=O)OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A1 P43005 2/20 0.55
TSHR P16473 4/20 0.50
LTA4H P09960 3/20 0.42
LMNA P02545 2/20 0.42
KDM4E B2RXH2 1/20 0.42
KMT2A Q03164 3/20 0.39
MEN1 O00255 1/20 0.39
CA12 O43570 2/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
GRM8 O00222 1/20 0.37
GRM6 O15303 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
GSR P00390 1/20 0.37
CYP1A2 P05177 1/20 0.37
GRIK1 P39086 1/20 0.37
GRM5 P41594 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL131049 1.00 SLC1A1 (0.55) SLC1A1TSHRLTA4HLMNAKDM4E
SCHEMBL1318285 1.00 SLC1A1 (0.55) SLC1A1TSHRLTA4HLMNAKDM4E
Hydrochloric Acid SCHEMBL1238805 0.98 SLC1A1 (0.53) SLC1A1TSHRLTA4HLMNAKDM4E
Hydrochloric Acid SCHEMBL624145 0.98 SLC1A1 (0.53) SLC1A1TSHRLTA4HLMNAKDM4E
Hydrochloric Acid SCHEMBL624146 0.98 SLC1A1 (0.53) SLC1A1TSHRLTA4HLMNAKDM4E
SCHEMBL20474981 0.91 SLC1A1 (0.47) SLC1A1TSHRLTA4HLMNAKDM4E
SCHEMBL10633361 0.91 SLC1A1 (0.47) SLC1A1TSHRLTA4HLMNAKDM4E
SCHEMBL10141318 0.88 TSHR (0.54) SLC1A1TSHRLTA4HLMNAKDM4E
SCHEMBL3417164 0.88 TSHR (0.54) SLC1A1TSHRLTA4HLMNAKDM4E
SCHEMBL2723398 0.88 SLC1A1 (0.51) SLC1A1TSHRLTA4HLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1767 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522747-B2 Coating compositions for use in creped paper product manufacturing and methods for producing the same SOLENIS TECHNOLOGIES, L.P. (US) 2026-01-13 US claimed
US-20250289842-A1 Processes for Making NAG-25, a Carbohydrate Targeting Moiety, and its Intermediates AMGEN INC. 2025-09-18 US claimed
CN-120136760-A Industrial production method of key intermediate of Nemactevir 沧州那瑞化学科技有限公司 2025-06-13 CN claimed
EP-4519278-A1 PROCESSES FOR MAKING NAG-25, A CARBOHYDRATE TARGETING MOIETY, AND ITS INTERMEDIATES Amgen Inc. (US) 2025-03-12 EP claimed
CN-119562958-A Methods for preparing NAG-25 carbohydrate targeting moieties and intermediates thereof 安进公司 2025-03-04 CN claimed
CN-119409588-A Caffeoyl amino acid methyl ester derivative and preparation method and application thereof 西北大学 2025-02-11 CN claimed
CN-119351754-A Recycling treatment method of copper-containing sludge 江西省金瑞环保科技有限公司 2025-01-24 CN claimed
CN-119241617-A 2 '-Deoxy-2' -fluoro-N4-substituted cytidine compound, preparation method and application thereof 河南省科学院高新技术研究中心 2025-01-03 CN claimed
CN-119161331-A Preparation method of degradation impurities in raltitrexed preparation 浙江皓格药业有限公司 2024-12-20 CN claimed
US-20240398552-A1 Scaffold For Nasal Tissue Engineering THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-12-05 US claimed
US-5567610-A EXPOSING HUMAN LYMPHOCYTES TO A LYSOMOTROPHIC AGENT MONOPEPTIDE METHYL ESTER OR DIPEPTIDE METHYL ESTER BIOINVENT INTERNATIONAL AB (SE) 1996-10-22 US claimed
EP-0701446-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1996-03-20 EP claimed
EP-0644887-A1 PROCESS FOR THE PREPARATION OF CLAVULANIC ACID. SMITHKLINE BEECHAM PLC (GB) 1995-03-29 EP claimed
WO-1994027627-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1994-12-08 WO claimed
CN-1095069-A Novel process for the preparation and/or purification of clavulanic acid or pharmaceutically acceptable salts or esters thereof SMITHKLINE BEECHAM PLC (GB) 1994-11-16 CN claimed
US-5300662-A Process for producing coumarin and derivatives thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1994-04-05 US claimed
WO-1993025557-A1 PROCESS FOR THE PREPARATION OF CLAVULANIC ACID SMITHKLINE BEECHAM PLC (GB) 1993-12-23 WO claimed
EP-0362031-B1 COMPOUNDS ACTIVE AGAINST MALARIA OF THE TISSUES, AND PROCESS FOR THEIR PREPARATION LA REGION WALLONNE (BE) 1993-07-07 EP claimed
EP-0362031-A1 Compounds active against malaria of the tissues, and process for their preparation LA REGION WALLONNE (BE) 1990-04-04 EP claimed
US-3936469-A Process for preparing N-carboxylic anhydrides of amino acids KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JA) 1976-02-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289842-A1 Processes for Making NAG-25, a Carbohydrate Targeting Moiety, and its Intermediates ENGASE, MAN2B2, GALNT2 SLC1A1 4275/4885TSHR 2215/4885LTA4H 3651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.